About Transcenta Therapeutics Transcenta (HKEX: 06628) is a global clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, ...

Digital GMP expectations are increasing, driven by Annex 11 and Annex 22, necessitating robust lifecycle management, data ...

In an era defined by rapid technological disruption and shifting economic paradigms, the traditional structures of Nigerian ...

Following the closure of Gujarat Kidney IPO, investor focus has now shifted to its allotment status. Gujarat Kidney IPO ...

The new Emerson DeltaV PKM library reportedly cuts months from drug development by providing pre-built specification elements ...

G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to ...

Now, Musunuru and colleagues are preparing a master clinical protocol to study a CRISPR therapy that's mostly the same as the one they used to treat baby KJ, except they plan to swap out the gene ...

Pluri (PLUR) announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell. Under the ongoing collaboration Remedy Cell’s ...

A look inside modern cosmetics factories—and how automation is helping brands keep up with demand, innovation, and regulatory ...

Under the ongoing collaboration Remedy Cell’s personnel, along with Pluri’s Contract Development and Manufacturing Organization (“CDMO”) division (PluriCDMO™), have successfully completed the full ...

Jessica Lin and Zhenqi (Pete) Shi from Genentech describe a novel machine learning approach to predicting retention times for ...

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ('HYTN” or the 'Company”), a pharmaceutical-grade cannabis ...